Cetera Investment Advisers Has $2.95 Million Holdings in Natera, Inc. $NTRA

Cetera Investment Advisers boosted its holdings in Natera, Inc. (NASDAQ:NTRA) by 33.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,486 shares of the medical research company’s stock after acquiring an additional 4,400 shares during the quarter. Cetera Investment Advisers’ holdings in Natera were worth $2,954,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust purchased a new stake in shares of Natera in the first quarter worth approximately $29,000. Northwestern Mutual Wealth Management Co. grew its holdings in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after buying an additional 106 shares in the last quarter. Hilltop National Bank purchased a new stake in Natera in the 2nd quarter valued at $33,000. Oliver Lagore Vanvalin Investment Group bought a new position in Natera during the 2nd quarter valued at $36,000. Finally, Summit Securities Group LLC bought a new position in Natera during the 1st quarter valued at $39,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a research report on Friday, November 7th. BNP Paribas Exane upgraded Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. UBS Group boosted their target price on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Barclays increased their price target on Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Canaccord Genuity Group lifted their price target on Natera from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Fifteen analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $220.88.

Natera Stock Up 0.3%

NTRA stock opened at $237.12 on Friday. The stock has a 50-day simple moving average of $191.21 and a two-hundred day simple moving average of $170.04. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $241.28. The firm has a market capitalization of $32.72 billion, a PE ratio of -103.55 and a beta of 1.75.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 1,867 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total value of $355,924.88. Following the completion of the transaction, the chief financial officer directly owned 64,126 shares in the company, valued at approximately $12,224,980.64. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roelof Botha sold 75,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the transaction, the director directly owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 308,366 shares of company stock worth $63,050,068 in the last three months. 5.63% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.